Inventor · disambiguated record
Maria Kreuzberg
Also filed as: KREUZBERG MARIA
15 granted patents·7 pending applications·68 citations·filing 2010–2023
91Inventor score
Files withGANYMED PHARMACEUTICALS GMBH8GANYMED PHARMACEUTICALS AG6BIONTECH AG4SAHIN UGUR3BioNTech SE1
Top patents by PatentIndex Score
22 records- 0193US11859008B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·2 cites·12 claims
- 0293US9718886B2Cancer therapy using CLDN6 target-directed antibodies in vivoSAHIN UGUR·Filed 2011·Granted Aug 1, 2017·13 cites·6 claims
- 0392US9487584B2Antibodies specific for claudin 6 (CLDN6)SAHIN UGUR·Filed 2010·Granted Nov 8, 2016·19 cites·20 claims
- 0492US9321842B2Antibodies for treatment of cancerSAHIN UGUR·Filed 2012·Granted Apr 26, 2016·14 cites·30 claims
- 0590US10233253B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Mar 19, 2019·7 cites·16 claims
- 0686US10604568B2Diagnosis and therapy of cancer involving cancer stem cellsBIONTECH AG·Filed 2014·Granted Mar 31, 2020·6 cites·10 claims
- 0785US11787862B2Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseasesBIONTECH AG·Filed 2017·Granted Oct 17, 2023·3 cites·32 claims
- 0885US2024092896A1Antibodies specific for claudin 6 (cldn6)GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 0984US2024101703A1Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 1083US2024084033A1Cancer therapy using cldn6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 1180US11541127B2Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 3, 2023·2 cites·28 claims
- 1278US2024059772A1Diagnosis and therapy of cancer involving cancer stem cellsBIONTECH AG·Filed 2023·Application pending·0 cites
- 1377US9902778B2Cancer therapy using CLDN6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Feb 27, 2018·1 cites·19 claims
- 1475US9932401B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Apr 3, 2018·1 cites·19 claims
- 1571US11858988B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·0 cites·24 claims
- 1670US2023270878A1Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 1770US2024158501A1Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseasesBioNTech SE·Filed 2023·Application pending·0 cites
- 1869US2021079113A1Cancer therapy using cldn6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 1968US10919974B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Feb 16, 2021·0 cites·12 claims
- 2067US11795218B2Diagnosis and therapy of cancer involving cancer stem cellsBIONTECH AG·Filed 2020·Granted Oct 24, 2023·0 cites·22 claims
- 2166US10745477B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Aug 18, 2020·0 cites·19 claims
- 2264US10844133B2Cancer therapy using CLDN6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Nov 24, 2020·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Maria Kreuzberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →